You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
領航醫藥生物科技(00399.HK)中期虧損收窄35.5%至1.1億港元
格隆匯 11-29 22:16

格隆匯11月29日丨領航醫藥生物科技(00399.HK)發佈中期業績,截至2019年9月30日止6個月,公司實現收益1112.6萬港元,同比增長10.7%;毛利105.2萬港元,同比增長16.1%;公司擁有人應占虧損1.1億港元,同比收窄35.5%;基本每股虧損7.55港仙;不派息。

公告表示,該財政期間,集團收益增加主要由於財政期間美容設備及產品貿易分部業務增加。於該財政期間,公司擁有人應占虧損下降主要由於財政期間就可換股債券投資公平值變動及於一間聯營公司權益減值虧損較上一財政期間下降所致。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account